The association between methotrexate metabolism-related gene polymorphisms and therapeutic efficacy and toxicity in patients with rheumatoid arthritis
Main finding · Improvement, SLC19A1 129 bp insertion alleleResult — go to the resultOdds ratio 2.564 95% CI 0.999–6.580Authors' conclusion
The 129 bp insertion of the SLC19A1 gene was positively correlated with better treatment response, suggesting it may be more directly involved in MTX carriage or metabolism, exerting a stable additive effect on drug efficacy.
Study context
- Population
- Rheumatoid arthritis (RA) patients treated with methotrexate (MTX)
- Participants
- 84 patients
- Comparison
- MTX metabolism-related gene polymorphisms and response to MTX
- Outcome
- Efficacy of MTX (improvement / response)
Methodological detailschi-square test or Fisher’s exact test, three gene models
- Chi-square test or Fisher’s exact test
- Three gene models
Main finding
Improvement, SLC19A1 129 bp insertion allele
Odds ratio
2.564
95% CI 0.999–6.580
P = 0.047
INS/INS + X/insvs X/X
OR 2.564 (95% CI 0.999–6.580); P = 0.047
As reported in the abstract
Further findings
Improvement, CTTGTACTTGTA of rs4149096 and C-allele of rs2291075
| OR (95% CI) | P value | ||
|---|---|---|---|
| CTTGTACTTGTA of rs4149096 and C-allele of rs2291075 | 4.145 (1.028–16.715) | P = 0.036 | |
| 0.050.21520Odds ratio (log scale) |
Good response, same allele (rs4149096 / rs2291075)
| OR (95% CI) | P value | ||
|---|---|---|---|
| CTTGTACTTGTA of rs4149096 and C-allele of rs2291075Negatively associated | 0.188 (0.042–0.827) | P = 0.036 | |
| 0.050.21520Odds ratio (log scale) |
Original publication
The association between methotrexate metabolism-related gene polymorphisms and therapeutic efficacy and toxicity in patients with rheumatoid arthritis. Arthritis Res Ther. Published 25 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →